CN110693902B - 枸橼酸铋钾在制备预防和治疗神经退行性疾病的药物方面的应用 - Google Patents
枸橼酸铋钾在制备预防和治疗神经退行性疾病的药物方面的应用 Download PDFInfo
- Publication number
- CN110693902B CN110693902B CN201910876601.1A CN201910876601A CN110693902B CN 110693902 B CN110693902 B CN 110693902B CN 201910876601 A CN201910876601 A CN 201910876601A CN 110693902 B CN110693902 B CN 110693902B
- Authority
- CN
- China
- Prior art keywords
- potassium citrate
- bismuth potassium
- protein
- disease
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910876601.1A CN110693902B (zh) | 2019-09-17 | 2019-09-17 | 枸橼酸铋钾在制备预防和治疗神经退行性疾病的药物方面的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910876601.1A CN110693902B (zh) | 2019-09-17 | 2019-09-17 | 枸橼酸铋钾在制备预防和治疗神经退行性疾病的药物方面的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110693902A CN110693902A (zh) | 2020-01-17 |
CN110693902B true CN110693902B (zh) | 2021-08-31 |
Family
ID=69195427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910876601.1A Active CN110693902B (zh) | 2019-09-17 | 2019-09-17 | 枸橼酸铋钾在制备预防和治疗神经退行性疾病的药物方面的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110693902B (zh) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI238718B (en) * | 2001-08-27 | 2005-09-01 | Hedonist Biochmical Technologi | Use of bismuth subgallate in inhibition of production of nitric oxide synthase |
US6514960B1 (en) * | 2001-08-27 | 2003-02-04 | Hedonist Biochemical Technologies Co., Ltd. | Use of bismuth subgallate in inhibition of production of nitric oxide synthase |
WO2009154819A2 (en) * | 2008-03-10 | 2009-12-23 | The Charlotte-Mecklenburg Hospital Authority | Treatment of inflammatory conditions and diseases with metal-thiols |
US20110086911A1 (en) * | 2009-10-13 | 2011-04-14 | Monash University | Novel bismuth(iii) nsaid compounds and methods for their use |
AU2009225298A1 (en) * | 2009-10-13 | 2011-04-28 | Monash University | Novel Bismuth(III) NSAID Compounds and Method for their Use |
US10150792B2 (en) * | 2010-11-08 | 2018-12-11 | Synthonics, Inc. | Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients |
-
2019
- 2019-09-17 CN CN201910876601.1A patent/CN110693902B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN110693902A (zh) | 2020-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sáez‐Valero et al. | Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer’s disease | |
Gee et al. | A selective p38α/β MAPK inhibitor alleviates neuropathology and cognitive impairment, and modulates microglia function in 5XFAD mouse | |
He et al. | Transmission of tauopathy strains is independent of their isoform composition | |
Cohen et al. | GSK3 inhibitors: development and therapeutic potential | |
Qu et al. | Dual signal amplification electrochemical biosensor for monitoring the activity and inhibition of the Alzheimer’s related protease β-secretase | |
Welander et al. | Aβ43 is more frequent than Aβ40 in amyloid plaque cores from Alzheimer disease brains | |
Inestrosa et al. | Amyloid–cholinesterase interactions: implications for Alzheimer’s disease | |
Yang et al. | Development of near-infrared fluorescent probes for use in Alzheimer’s disease diagnosis | |
Meraz‐Ríos et al. | Tau oligomers and aggregation in Alzheimer’s disease | |
Brunden et al. | Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies | |
Yao et al. | Discovery of novel tacrine–pyrimidone hybrids as potent dual AChE/GSK-3 inhibitors for the treatment of Alzheimer’s disease | |
Kim et al. | Inhibitory RNA aptamers of tau oligomerization and their neuroprotective roles against proteotoxic stress | |
Liu et al. | Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property | |
Baglietto-Vargas et al. | Dual roles of Aβ in proliferative processes in an amyloidogenic model of Alzheimer’s disease | |
Li et al. | Effects of galantamine on β-amyloid release and beta-site cleaving enzyme 1 expression in differentiated human neuroblastoma SH-SY5Y cells | |
Hassan et al. | Electrochemical biosensors for the detection and study of α-synuclein related to Parkinson's disease–a review | |
Hou et al. | A New Motif in the N‐Terminal of Acetylcholinesterase Triggers Amyloid‐β Aggregation and Deposition | |
Zheng et al. | Development of DNA aptamer as a β-amyloid aggregation inhibitor | |
CN110693902B (zh) | 枸橼酸铋钾在制备预防和治疗神经退行性疾病的药物方面的应用 | |
Deters et al. | Substrate-specific reduction of PP2A activity exaggerates tau pathology | |
US20020022242A1 (en) | Diagnostic test for alzheimer's disease | |
WO2013073219A1 (ja) | 神経変性疾患関連タンパク質の不溶性凝集体の製造方法 | |
Perea et al. | p38 activation occurs mainly in microglia in the P301S Tauopathy mouse model | |
Wang et al. | Detection of Amyloid-β (1–42) Aggregation With a Nanostructured Electrochemical Sandwich Immunoassay Biosensor | |
Beck et al. | An autopsy case of progressive supranuclear palsy treated with monoclonal antibody against tau |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20200117 Assignee: Suzhou Nicholas Intelligent Equipment Co.,Ltd. Assignor: SHENZHEN University Contract record no.: X2022980024373 Denomination of invention: Application of bismuth potassium citrate in preparation of drugs for prevention and treatment of neurodegenerative diseases Granted publication date: 20210831 License type: Common License Record date: 20221201 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20200117 Assignee: Shenzhen Dongfang Renshou Life Technology Co.,Ltd. Assignor: SHENZHEN University Contract record no.: X2022980025926 Denomination of invention: Application of bismuth potassium citrate in preparation of drugs for prevention and treatment of neurodegenerative diseases Granted publication date: 20210831 License type: Common License Record date: 20221211 |